Reappraisal of GLP-1 receptor agonists in older adults
Experts call attention to a gap: most diabetes drug trials exclude elderly patients and frailty risks, prompting urgent research into safe use of these popular agents in older adults.
This Trends in Endocrinology and Metabolism perspective critically evaluates GLP-1 receptor agonist use in older adults, highlighting the disconnect between evidence from predominantly middle-aged trial populations and the real-world use in elderly patients with sarcopenia risk and frailty. The authors call for dedicated geriatric sub-studies and individualized benefit-risk assessment accounting for lean mass, nutritional status, and fall risk in older adults receiving these agents.
What the study was
- Study design
- review
- Population
- Older adults (elderly) with cardiometabolic conditions receiving GLP-1 receptor agonists (review population)
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Trends in Endocrinology and Metabolism
Why it surfaced
Timely clinical commentary in a high-impact journal on a major unresolved issue—GLP-1 safety in the elderly is underexplored despite explosive market growth of semaglutide/tirzepatide; raises actionable concerns about muscle wasting in a vulnerable population; relevant to both cardiovascular_metabolic (GLP-1) and aging_longevity; limited by narrative/opinion design.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.